A practical reference on metabolic research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-20 and is reviewed periodically as new material appears.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
=== Gene gun === Gene gun delivery ballistically accelerates plasmid DNA (pDNA) that has been absorbed onto gold or tungsten microparticles into the target cells, using compressed helium as an accelerant.
compared perianal injectable bulking agents to sphincter training and biofeedback, and found the former to be superior. Both methods lead to an improvement of FI, but comparisons of St Mark's scores between the groups showed no difference between treatments. Anal manometry is sometimes used to investigate changes in the anal canal before and after the procedure. Usually mean anal resting pressure and mean anal squeeze pressure are the parameters used. Improvements in these measurements are often, but not always reported up to 3–12 months after the procedure. These improvements are not always maintained after 12 months. The length of the anal canal has also been reported to increase following the procedure. In one report, dextranomer did not increase anal resting or squeeze pressures. In the same study, dextranomer injections were found to be no different to biofeedback. There is limited research available on this topic, and these publications are mostly of poor quality. Apart from the available research, most of the claims of benefit of these procedures is anecdotal. One author criticized these procedures, stating that simply narrowing the anal canal was an instinctive and naïve solution which does not consider the complex pathopysiological mechanisms of FI. They suggested that these treatments are in theory suitable only for passive and minor forms of FI. Concerns have been raised about migration of the particles (in the case of Durasphere) away from the site of injection, or the total resorption of the material (in the case of hyaluronic acid and hydroxyl coaptite).
Escitalopram discontinuation, particularly abruptly, may cause certain withdrawal symptoms such as "electric shock" sensations, colloquially called "brain shivers" or "brain zaps" by those affected. Frequent symptoms in one study were dizziness (44%), muscle tension (44%), chills (44%), confusion or trouble concentrating (40%), amnesia (28%), and crying (28%). Very slow tapering is recommended. There have been spontaneous reports of discontinuation of escitalopram and other SSRIs and SNRIs, especially when abrupt, leading to dysphoric mood, irritability, agitation, anxiety, headache, lethargy, emotional lability, insomnia, and hypomania. Other symptoms such as panic attacks, hostility, aggression, impulsivity, akathisia (psychomotor restlessness), mania, worsening of depression, and suicidal ideation can emerge when the dose is adjusted down.
== History == The natural immunity of snakes to their own venom was observed at least as early as 1767, by Felice Fontana in his work Ricerche Fisiche sopra il Veleno della Vipera (Physical Research on the Venom of the Viper). Scottish surgeon and naturalist Patrick Russell also noted in the late 18th century that snakes were not affected by their own venom. Surgeon-Major Edward Nicholson wrote in the November 1870 Madras Medical Journal that he had witnessed a Burmese snake-catcher inoculating himself with cobra venom. However, the snake-catcher was unsure whether this was actually effective and therefore continued to treat his snakes with care. The notion of inducing immunity to venom was tested in laboratories around the world. In 1887, Dr. Henry Sewall in Michigan achieved artificial immunity to rattlesnake (Sistrurus catenatus catenatus) venom in pigeons by repeated inoculation of venom, starting with a sub-lethal dose and progressively increasing in strength until resistance developed to doses seven times the lethal dose in untreated pigeons. From 1889 to 1892, Maurice Kaufmann at the École nationale vétérinaire d'Alfort studied the effect of successive inoculations of weak doses of Vipera aspis venom on animals. Although proving that a greater resistance to low doses was possible, Kauffman was unable to achieve complete immunity against the venom at the lethal dose. The breakthrough came with the use of serum from an immunized animal to counter the effects in an unexposed animal.
Sources: en.wikipedia.org
== Arts and entertainment == Laurel and Hardy, a comedy double act during the early Classical Hollywood era of American cinema "Little Hide", 1998 single by Snow Patrol Lovehammers, a Chicago-based band Love Hina, a 1998 popular manga (and anime) series by author Ken Akamatsu The Lurking Horror, an interactive fiction game released in 1987
=== Peptide synthesis/ACTH === The first chemical synthesis of an active peptide hormone, the nine amino acid cyclic peptide, oxytocin, was achieved in 1954 by du Vigneaud for which he was awarded the Nobel Prize. At the same time, the isolation and structure determination of the anterior pituitary hormone, ACTH, was being pursued in three laboratories. The peptide was eventually determined to be 39 amino acids in length, however enzymatic and mild acid cleavage suggested that a structure comprising only the first 24 amino acids had full biological activity. It was apparent from the outset that ACTH contained the amino acid Arginine and thus methods had to be developed for the incorporation of this basic amino acid into peptides. Hofmann and his group set about this task. Their efforts led to the synthesis of the melanocyte stimulating hormone, β-MSH, which corresponds to the first 13 amino acids of ACTH and to the synthesis of a fully active ACTH peptide corresponding to the amino acid sequence of the first 23 amino acids. In the course of the peptide synthetic work on ACTH, a novel chain cleavage was observed at an acyl-proline linkage while removing protecting groups using metallic sodium in liquid ammonia. This unexpected reaction has subsequently proved useful in special analytical cases.
Soft tissues have the potential to undergo large deformations and still return to the initial configuration when unloaded, i.e. they are hyperelastic materials, and their stress-strain curve is nonlinear. The soft tissues are also viscoelastic, incompressible and usually anisotropic. Some viscoelastic properties observable in soft tissues are: relaxation, creep and hysteresis. In order to describe the mechanical response of soft tissues, several methods have been used. These methods include: hyperelastic macroscopic models based on strain energy, mathematical fits where nonlinear constitutive equations are used, and structurally based models where the response of a linear elastic material is modified by its geometric characteristics.
Sources: en.wikipedia.org
== Part 2 == The second part runs approximately two-and-a-half hours and follows Metallica at the start of their Wherever We May Roam Tour in Europe through to the Guns N' Roses/Metallica Stadium Tour of 1992. Included are performances of "For Whom the Bell Tolls" from Donington on August 17, 1991, "Enter Sandman" from the MTV Video Music Awards on September 5, "Harvester of Sorrow" from Moscow on September 28, "Sad but True" from the Day on the Green festival in Oakland, California on October 12, "Enter Sandman" from the Freddie Mercury Tribute Concert on April 20, 1992, and "Nothing Else Matters" from Phoenix on August 25. Jason Newsted after a concert in Portland, Maine, is seen making sandwiches to take back to a hotel with him instead of ordering room-service. His response to being called a cheapskate is "I got plans for those millions and it ain't for fucking sandwiches!" Sebastian Bach is seen joking with Slash and Lars Ulrich in Metallica's dressing room at RFK Stadium in Washington, D.C. prior to the opening concert of the joint tour with Guns N' Roses. Bach humorously imitates MTV host Riki Rachtman, and former Metallica guitarist Dave Mustaine. The band also encounter Spinal Tap, who jokingly ask them about the similarities between their album's covers. This part of the documentary also includes two music videos:
Darglitazone (previously known as CP 86325-2) is a member of the thiazolidinedione class of drugs and an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), an orphan member of the nuclear receptor superfamily of transcription factors. It has a variety of insulin-sensitizing effects, such as improving glycemic and lipidemic control, and was studied by Pfizer as a potential treatment of metabolic disorders such as type 2 diabetes mellitus. Its development was terminated in 1999.
Another Communist, Li Jingxuan, became his secretary-general. Under Liu Yuan'an's influence, Liu Wenhui supposedly expressed interest in inviting the prominent communist Wu Yuzhang to head the Chengdu University and funded progressive newspapers. Liu also asked his communist advisor to send political workers for Liu Wenhui's army. Peng Dixian and Shu Guofan's 1990 biography of Liu, written in the People's Republic by communist-aligned authors, casts these instances as evidence of his "inclinations towards revolution" but noted that these progressive leanings were shallow. In August 1926, Liu Wenhui and Liu Chengxun jointly issued a circular telegram denouncing Wu Peifu, accusing the Beiyang warlord of bringing chaos to Sichuan. This signaled their alignment with the Nationalist cause. In December 1926, the Northern Expedition captured Wuhan, and Liu sent a delegation under Zhang Zhihe [zh] to seek recognition from the new Nationalist government. He joined the Kuomintang and was appointed the commander of the 24th Army of the National Revolutionary Army. After Liu's appointment as commander of the 24th Army, he moved to Chengdu, leaving the defense of Yibin to Tan Xiaolou (覃筱楼), a former bandit leader Liu had recruited. Here, he joined Deng Xihou and Tian Songyao, who had already established themselves in the city. All three were classmates from their Baoding days and ruled as a united front in public, but privately schemed to expand their individual power.
production of the drug(s) or device(s) being evaluated staff salaries for the designers and administrators of the trial payments to the contract research organization, the site management organization (if used) and any outside consultants payments to local researchers and their staff for their time and effort in recruiting test subjects and collecting data for the sponsor the cost of study materials and the charges incurred to ship them communication with the local researchers, including on-site monitoring by the CRO before and (in some cases) multiple times during the study one or more investigator training meetings expense incurred by the local researchers, such as pharmacy fees, IRB fees and postage any payments to subjects enrolled in the trial the expense of treating a test subject who develops a medical condition caused by the study drug These expenses are incurred over several years. In the US, sponsors may receive a 50 percent tax credit for clinical trials conducted on drugs being developed for the treatment of orphan diseases. National health agencies, such as the US National Institutes of Health, offer grants to investigators who design clinical trials that attempt to answer research questions of interest to the agency. In these cases, the investigator who writes the grant and administers the study acts as the sponsor, and coordinates data collection from any other sites. These other sites may or may not be paid for participating in the study, depending on the amount of the grant and the amount of effort expected from them.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.